New developments of clinical trial in immunotherapy for alzheimer's disease

Current Pharmaceutical Biotechnology

Volumn 16, Issue 6, 2015, Pages 484-491

  Yang, Cece ^a   Xiao, Shifu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer s disease; Antibodies; Clinical trials; Immunotherapy; Vaccines

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BAPINEUZUMAB; CRENEZUMAB; GANTENERUMAB; IMMUNOGLOBULIN; PONEZUMAB; SOLANEZUMAB; TAU PROTEIN; VANUTIDE CRIDIFICAR; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; CLINICAL TRIAL (TOPIC); IMMUNIZATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION; MOLECULAR TARGETED THERAPY;

EID: 84928957555     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920101606150407112319     Document Type: Article

References (69)

1. Wimo, A.; Jönsson, L.; Bond, J.; Prince, M.; Winblad, B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers. Dement., 2013, 9(1), 1-11.e3.
2. Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascadehypothesis. Science, 1992, 256, 184-185.
3. Tanzi, R. E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120, 545-555.
4. Wisniewski, T.; Goni, F. Immunotherapy for Alzheimer's disease. Biochem. Pharmacol., 2014.
5. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholoden-ko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wo-gulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-likepathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
6. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-919.
7. Weiner, H.L.; Frenkel, D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol., 2006, 6, 404-416.
8. Bayer, A.J.; Bullock, R.; Jones, R.W.; Wilkinson, D.; Paterson, K.R.; Jenkins, L.; Millais, S.B.; Donoghue, S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology, 2005, 64, 94-101.
9. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R. W.; Bullock, R.; Love, S.; Neal, J.W.; Zo-tova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-223.
10. Boche, D.; Donald, J.; Love, S.; Harris, S.; Neal, J.W.; Holmes, C.; Nicoll, J.A. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta. Neuropathol., 2010, 120, 13-20.
11. Wisniewski, T. Active immunotherapy for Alzheimer's disease. Lancet. Neurol., 2012, 11, 571-572.
12. Holtzman, D.M.; Mandelkow, E.; Selkoe, D.J. Alzheimer disease in 2020. Cold. Spring Harb. Perspect. Med., 2012, 2.
13. Small, S.A.; Duff, K. Linking Abeta and tau in late-onset Alzheimer's disease: A dual pathway hypothesis. Neuron, 2008, 60, 534-542.
14. Castellani, R.J.; Lee, H.G.; Zhu, X.; Perry, G.; Smith, M.A. Alzheimer disease pathology as a host response. J. Neuropathol. Exp. Neurol., 2008, 67, 523-531.
15. Fox, N.C.; Black, R.S.; Gilman, S.; Rossor, M.N.; Griffith, S.G.; Jenkins, L.; Koller, M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005, 64, 1563-1572.
16. Vellas, B.; Black, R.; Thal, L.J.; Fox, N.C.; Daniels, M.; McLennan, G.; Tompkins, C.; Leibman, C.; Pomfret, M.; Grundman, M. Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr. Alzheimer. Res., 2009, 6, 144-151.
17. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogo-zo, J.M. Clinicaleffects of Abetaimmunization (AN1792) in patients with AD in an interruptedtrial. Neurology, 2005, 64, 1553-1562.
18. Pride, M.; Seubert, P.; Grundman, M.; Hagen, M.; Eldridge, J.; Black, R. S. Progress in the active immunotherapeutic approach to Alzheimer's disease: Clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis., 2008, 5, 194-196.
19. Ryan, J. M.; Grundman, M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J. Alz-heimers. Dis., 2009, 17, 243.
20. http://www.clinicaltrials.gov/ct2/results?term=ACC-001&Search= Search
21. Winblad, B.; Andreasen, N.; Minthon, L.; Floesser, A.; Imbert, G.; Dumortier, T.; Maguire, R.P.; Blennow, K.; Lundmark, J.; Staufenbiel, M.; Orgogozo, J.M.; Graf, A. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet. Neurol., 2012, 11, 597-604.
22. Panza, F.; Logroscino, G.; Imbimbo, B. P.; Solfrizzi, V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr. Opin. Psychiatr., 2014, 27, 128-137.
23. Schneeberger, A.; Mandler, M.; Otawa, O.; Zauner, W.; Mattner, F.; Schmidt, W. Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J. Nutr. Health Aging, 2009, 13, 264-267.
24. Boche, D.; Donald, J.; Love, S.; Harris, S.; Neal, J.W.; Holmes, C.; Nicoll, J.A. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol., 2010, 120(1), 13-20.
25. http://www.clinicaltrials.gov/ct2/results?term=UB+311&Search=S earch
26. http://www.clinicaltrials.gov/ct2/results?term=+V950+&Search= Search
27. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 8850-8855.
28. Schroeter, S.; Khan, K.; Barbour, R.; Doan, M.; Chen, M.; Guido, T.; Gill, D.; Basi, G.; Schenk, D.; Seubert, P.; Games, D. Immuno-therapy reduces vascular amyloid-beta in PDAPP mice. J. Neuro-sci., 2008, 28, 6787-6793.
29. Solomon, B. Immunological approach for the treatment of Alzheimer's disease. J. Mol. Neurosci., 2003, 20, 283-286.
30. Morgan, D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis., 2005, 2, 261-266.
31. Black, R.S.; Sperling, R.A.; Safirstein, B.; Motter, R.N.; Pallay, A.; Nichols, A.; Grundman, M. A single ascending dose studyofbapi-neuzumab in patientswith Alzheimer disease. Alzheimer. Dis. As-soc.Disord., 2010, 24, 198-203.
32. Salloway, S.; Sperling, R.; Gilman, S.; Fox, N.C.; Blennow, K.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Doody, R.; van Dyck, C.H.; Mulnard, R.; Barakos, J.; Gregg, K.M.; Liu, E.; Lieberburg, I.; Schenk, D.; Black, R.; Grundman, M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 2009, 73, 2061-2070.
33. Sperling, R.; Salloway, S.; Brooks, D.J.; Tampieri, D.; Barakos, J.; Fox, N.C.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Porsteinsson, A.P.; Lieberburg, I.; Arrighi, H.M.; Morris, K.A.; Lu, Y.; Liu, E.; Gregg, K.M.; Brashear, H.R.; Kinney, G.G.; Black, R.; Grundman, M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol., 2012, 11, 241-249.
34. Blennow, K.; Zetterberg, H.; Rinne, J.O.; Salloway, S.; Wei, J.; Black, R.; Grundman, M.; Liu, E. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients-with mild to moderate Alzheimer disease. Arch. Neurol., 2012, 69, 1002-1010.
35. Salloway, S.; Sperling, R.; Fox, N.C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Porsteinsson, A.P.; Ferris, S.; Reichert, M.; Ketter, N.; Nejadnik, B.; Guenzler, V.; Mi-loslavsky, M.; Wang, D.; Lu, Y.; Lull, J.; Tudor, I.C.; Liu, E.; Grundman, M.; Yuen, E.; Black, R.; Brashear, H.R. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med., 2014, 370, 322-333.
36. Castellani, R.J.; Perry, G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch. Med. Res., 2012, 43, 694-698.
37. Crespi, G.A.; Ascher, D.B.; Parker, M.W.; Miles, L.A. Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β. Acta Crystallogr. F Struct. Biol. Commun., 2014, 70(Pt 3), 374-377.
38. Siemers, E.R.; Friedrich, S.; Dean, R.A.; Gonzales, C.R.; Farlow, M.R.; Paul, S.M.; Demattos, R.B. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol., 2010, 33, 67-73.
39. Uenaka, K.; Nakano, M.; Willis, B.A.; Friedrich, S.; Ferguson-Sells, L.; Dean, R.A.; Ieiri, I.; Siemers, E.R. Comparison of phar-macokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Clin. Neu-ropharmacol., 2012, 35, 25-29.
40. Samadi, H.; Sultzer, D. Solanezumab for Alzheimer's disease. Expert. Opin. Biol. Ther., 2011, 11, 787-798.
41. Doody, R.S.; Thomas, R.G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S.; Siemers, E.; Liu-Seifert, H.; Mohs, R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med., 2014, 370, 311-321.
42. Grundman, M.; Dibernardo, A.; Raghavan, N.; Krams, M.; Yuen, E. 2012: A watershed year for Alzheimer's disease research. J. Nutr. Health. Aging, 2013, 17, 51-53.
43. Karran, E.; Hardy, J. Antiamyloid therapy for Alzheimer's disease--are we on the right road?N. Engl. J. Med., 2014, 370, 377-378.
44. Moulder, K.L.; Snider, B.J.; Mills, S.L.; Buckles, V.D.; Santacruz, A.M.; Bateman, R.J.; Morris, J.C. Dominantly inherited Alzheimer network: Facilitating research and clinicaltrials. Alzheimers Res. Ther., 2013, 5(5), 48.
45. Mills, S.M.; Mallmann, J.; Santacruz, A.M.; Fuqua, A.; Carril, M.; Aisen, P.S.; Althage, M.C.; Belyew, S.; Benzinger, T.L.; Brooks, W.S.; Buckles, V.D.; Cairns, N.J.; Clifford, D.; Danek, A.; Fagan, A.M.; Farlow, M.; Fox, N.; Ghetti, B.; Goate, A.M.; Heinrichs, D.; Hornbeck, R.; Jack, C.; Jucker, M.; Klunk, W.E.; Marcus, D.S.; Martins, R.N.; Masters, C.M.; Mayeux, R.; McDade, E.; Morris, J.C.; Oliver, A.; Ringman, J.M.; Rossor, M.N.; Salloway, S.; Schofield, P.R.; Snider, J.; Snyder, P.; Sperling, R.A.; Stewart, C.; Thomas, R.G.; Xiong, C.; Bateman, R.J. Preclinical trials in auto-somal dominant AD: Implementation of the DIAN-TU trial. Rev. Neurol. (Paris)., 2013, 169(10), 737-743.
46. Sperling, R.A.; Rentz, D.M.; Johnson, K.A.; Karlawish, J.; Dono-hue, M.; Salmon, D.P.; Aisen, P. The A4 study: Stopping AD before symptoms begin? Sci. Transl. Med., 2014, 6(228), 228fs13.
47. Farlow, M.R.; Brosch, J.R. Immunotherapy for Alzheimer's disease. Neurol. Clin., 2013, 31, 869-878.
48. La Porte, S.L.; Bollini, S.S.; Lanz, T.A.; Abdiche, Y.N.; Rusnak, A.S.; Ho, W.H.; Kobayashi, D.; Harrabi, O.; Pappas, D.; Mina, E.W.; Milici, A.J.; Kawabe, T.T.; Bales, K.; Lin, J.C.; Pons, J. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol., 2012, 421, 525-536.
49. Freeman, G.B.; Lin, J.C.; Pons, J.; Raha, N.M. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomol-gus monkeys with 12-week recovery period. J. Alzheimers. Dis., 2012, 28, 531-541.
50. Burstein, A.H.; Zhao, Q.; Ross, J.; Styren, S.; Landen, J.W.; Ma, W.W.; McCush, F.; Alvey, C.; Kupiec, J.W.; Bednar, M.M. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin. Neuropharmacol., 2013, 36, 8-13.
51. Landen, J.W.; Zhao, Q.; Cohen, S.; Borrie, M.; Woodward, M.; Billing, C.B., Jr.; Bales, K.; Alvey, C.; McCush, F.; Yang, J.; Kupiec, J.W.; Bednar, M.M. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin. Neuropharmacol., 2013, 36, 14-23.
52. Adolfsson, O.; Pihlgren, M.; Toni, N.; Varisco, Y.; Buccarello, A.L.; Antoniello, K.; Lohmann, S.; Piorkowska, K.; Gafner, V.; Atwal, J. K.; Maloney, J.; Chen, M.; Gogineni, A.; Weimer, R.M.; Mortensen, D.L.; Friesenhahn, M.; Ho, C.; Paul, R.; Pfeifer, A.; Muhs, A.; Watts, R.J. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci., 2012, 32, 9677-9689.
53. Garber, K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat. Biotechnol., 2012, 30, 731-732.
54. Miller, G. Alzheimer's research. Stopping Alzheimer's before it starts. Science (New York, N.Y.), 2012, 337, 790-792.
55. Bohrmann, B.; Baumann, K.; Benz, J.; Gerber, F.; Huber, W.; Knoflach, F.; Messer, J.; Oroszlan, K.; Rauchenberger, R.; Richter, W. F.; Rothe, C.; Urban, M.; Bardroff, M.; Winter, M.; Nordstedt, C.; Loetscher, H. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheim-ers. Dis., 2012, 28, 49-69.
56. Novakovic, D.; Feligioni, M.; Scaccianoce, S.; Caruso, A.; Pic-cinin, S.; Schepisi, C.; Errico, F.; Mercuri, N.B.; Nicoletti, F.; Nis-tico, R. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug. Des. Devel. Ther., 2013, 7, 1359-1364.
57. Sperling, R.A.; Jack, C.R., Jr.; Black, S.E.; Frosch, M.P.; Green-berg, S.M.; Hyman, B. T.; Scheltens, P.; Carrillo, M.C.; Thies, W.; Bednar, M.M.; Black, R.S.; Brashear, H.R.; Grundman, M.; Siemers, E.R.; Feldman, H.H.; Schindler, R.J. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Round-table Workgroup. Alzheimers. Dement., 2011, 7, 367-385.
58. Sakai, K.; Yamada, M. Aβ immunotherapy for Alzheimer's disease. Brain Nerve, 2013, 65(4), 461-468.
59. Zago, W.; Schroeter, S.; Guido, T.; Khan, K.; Seubert, P.; Yed-nock, T.; Schenk, D.; Gregg, K. M.; Games, D.; Bard, F.; Kinney, G. G. Vascular alterations in PDAPP mice after anti-Abeta immu-notherapy: Implications for amyloid-related imaging abnormalities. Alzheimer’s Dement., 2013, 9, S105-115.
60. Wuest, D.M.; Lee, K.H. Amyloid-beta concentration and structure influences the transport and immunomodulatory effects of IVIG. J. Neurochem., 2014, 130(1), 136-44.
61. Dodel, R.C.; Du, Y.; Depboylu, C.; Hampel, H.; Frolich, L.; Haag, A.; Hemmeter, U.; Paulsen, S.; Teipel, S.J.; Brettschneider, S.; Spottke, A.; Nolker, C.; Moller, H.J.; Wei, X.; Farlow, M.; Som-mer, N.; Oertel, W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 1472-1474.
62. Relkin, N.R.; Szabo, P.; Adamiak, B.; Burgut, T.; Monthe, C.; Lent, R.W.; Younkin, S.; Younkin, L.; Schiff, R.; Weksler, M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging, 2009, 30, 1728-1736.
63. Relkin, N.; Bettger, L.; Tsakanikas, D.; Ravdin, L. Three-year follow-up on the IVIG for Alzheimer's phase II study. Alzheimer's & Dementia, 2012, 8, P589.
64. Dodel, R.; Rominger, A.; Bartenstein, P.; Barkhof, F.; Blennow, K.; Forster, S.; Winter, Y.; Bach, J.P.; Popp, J.; Alferink, J.; Wilt-fang, J.; Buerger, K.; Otto, M.; Antuono, P.; Jacoby, M.; Richter, R.; Stevens, J.; Melamed, I.; Goldstein, J.; Haag, S.; Wietek, S.; Farlow, M.; Jessen, F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neu-rol., 2013, 12, 233-243.
65. Loeffler, D.A. Intravenous immunoglobulin and Alzheimer's disease: what now? J. Neuroinflammation, 2013, 10, 70.
66. Yoshiyama, Y.; Lee, V.M.; Trojanowski, J.Q. Therapeutic strategies for tau mediatedneurodegeneration. J. Neurol. Neurosurg. Psychiatr., 2013, 84, 784-795.
67. Lambracht-Washington, D.; Rosenberg, R.N. Active DNA Abeta42 vaccination as immunotherapy for Alzheimer disease. Transl. Neu-rosci., 2012, 3, 307-313.
68. Robert, R.; Wark, K.L. Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch. Biochem. Biophys., 2012, 526, 132-138.
69. Rabinovich-Nikitin, I.; Rakover, I.S.; Becker, M.; Solomon, B. Beneficial effect of antibodies against beta- secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice. PloS One, 2012, 7, e46650.